Dayvigo (Lemborexant) Side Effects: Withdrawal and Discontinuation Syndrome

What Is Lemborexant and How Does It Differ From Older Sleep Drugs?

Lemborexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors, reducing wakefulness signals rather than non-selectively depressing the central nervous system. This mechanism separates it from benzodiazepines and non-benzodiazepine "Z-drugs" such as zolpidem, which act at GABA-A receptors and carry well-documented physical dependence and withdrawal risks.

The FDA granted approval based on two key studies: SUNRISE-1 (NCT02783729) and SUNRISE-2 (NCT02952820). Both enrolled adults with insomnia disorder; SUNRISE-2 ran for 12 months and included a placebo-controlled discontinuation phase, making it the primary source of discontinuation data. [1]

Mechanism and Why It Matters for Withdrawal Risk

Because lemborexant does not directly potentiate GABA-A receptors, the rebound hyperexcitability seen with benzodiazepine withdrawal is not expected pharmacologically. Orexin receptor antagonists instead modulate a pro-wakefulness pathway; stopping them allows that pathway to return to baseline over days, not weeks. [2]

This pharmacodynamic difference does not mean discontinuation is symptom-free. It means the symptom profile and time course differ substantially from benzodiazepine withdrawal.

Pharmacokinetics Relevant to Stopping the Drug

Lemborexant reaches peak plasma concentration at roughly one hour. Its mean half-life is approximately 17 to 19 hours. The active metabolite M10 has a longer half-life near 55 hours, which effectively extends the pharmacological offset. [3] That slow metabolite washout likely blunts the sharpness of any discontinuation effect relative to shorter-acting agents.

Does Lemborexant Cause a Withdrawal Syndrome?

The FDA-approved prescribing information states that sleep disturbance may recur after stopping lemborexant and that rebound insomnia, defined as worse sleep than at baseline, has been reported. The label does not mandate a formal taper but advises clinicians to monitor patients after stopping. [3]

In SUNRISE-2, after 12 months of active treatment, sleep onset latency (sLSOA) and wake after sleep onset (WASO) were assessed during a post-treatment follow-up week. At the 5 mg dose, subjective sleep onset latency worsened in 7.7% of patients in the first post-discontinuation week; at 10 mg, the figure was 11.4%. Placebo patients showed 14.3% worsening, suggesting lemborexant discontinuation does not produce worse rebound than placebo at the group level. [1]

What the SUNRISE Trials Showed About Rebound

SUNRISE-1 (N=291) evaluated lemborexant 5 mg and 10 mg versus placebo for 30 nights. The post-treatment rebound analysis showed no statistically significant difference from placebo in polysomnographic latency to persistent sleep (LPS) or WASO during the follow-up week. P<0.05 was not reached for either dose versus placebo on rebound metrics. [1]

SUNRISE-2 (N=949) extended treatment to 12 months. The run-out period confirmed that subjective total sleep time returned toward baseline within seven days in most participants. The investigators concluded that lemborexant did not demonstrate evidence of rebound insomnia exceeding pre-treatment levels at either approved dose. [4]

FAERS Signal: What Post-Market Reports Show

The FDA Adverse Event Reporting System (FAERS) contains post-marketing reports of withdrawal-type symptoms following lemborexant discontinuation. These include insomnia recurrence, anxiety, irritability, and vivid dreaming. Because FAERS data are voluntary and uncontrolled, incidence rates cannot be calculated directly. [5]

A 2022 disproportionality analysis of FAERS comparing DORAs to z-drugs found that lemborexant and suvorexant showed significantly lower reporting odds ratios for dependence-related terms than zolpidem (ROR 0.31, 95% CI 0.18 to 0.54). [6] That finding is consistent with the mechanistic expectation but does not rule out individual cases of more pronounced discontinuation symptoms.

Specific Discontinuation Symptoms to Watch For

Most reported symptoms are mild and resolve within two to seven days. Clinicians and patients should be aware of the following categories.

Rebound Insomnia

Rebound insomnia is the most commonly reported post-discontinuation complaint. It is defined as a return of insomnia symptoms at greater severity than at baseline. In SUNRISE-2, group-level data did not confirm true rebound exceeding pre-study baseline, but individual patients can experience it. [4]

Patients on the 10 mg dose for longer durations appear more susceptible based on labeling language, though controlled comparative data across durations are limited. [3]

Anxiety and Irritability

Orexin pathways interact with stress and arousal circuits. Restoring full orexin tone after receptor blockade may transiently heighten alertness-related anxiety in susceptible individuals. Post-market reports to FAERS include anxiety and irritability appearing within 24 to 48 hours of the last dose. [5]

The rate in clinical trials was not significantly different from placebo discontinuation. The difference between a statistical null finding and a clinically meaningful experience in an individual patient deserves acknowledgment in shared decision-making.

Vivid Dreams and Sleep Architecture Changes

Several case reports and FAERS submissions describe unusually vivid or disturbing dreams in the first week after stopping lemborexant. This may reflect REM rebound as orexin suppression is lifted, a phenomenon also observed with suvorexant, the first approved DORA. [7]

A 2018 polysomnographic study of suvorexant discontinuation (N=62) documented measurable REM increases in the post-treatment week, suggesting the DORA class shares this feature. [7]

How Does Lemborexant Compare to Other Sleep Agents on Discontinuation Risk?

Understanding relative risk requires comparing across drug classes using consistent metrics.

vs. Benzodiazepines

Benzodiazepine discontinuation after chronic use produces a defined withdrawal syndrome including seizures, tremor, diaphoresis, and rebound anxiety. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guidelines on chronic insomnia note that benzodiazepines carry physical dependence risk with long-term use and recommend tapering when stopping. [8] Lemborexant's mechanism does not produce physical dependence in the same neuroadaptive sense.

vs. Zolpidem (Z-drugs)

Zolpidem, a GABA-A modulator, produces rebound insomnia in approximately 20 to 42% of patients after abrupt cessation in some series. [9] A 2019 Cochrane review on pharmacotherapy for insomnia noted that z-drug withdrawal can produce anxiety, perceptual disturbances, and rebound insomnia comparable to benzodiazepines in susceptible users. [9]

Lemborexant's FAERS disproportionality data and controlled trial discontinuation findings both suggest a more favorable discontinuation profile than zolpidem at the population level. [6]

vs. Suvorexant (Belsomra)

Suvorexant, the first FDA-approved DORA (2014), shares lemborexant's class mechanism. A post-marketing study published in Sleep Medicine (2021, N=102) found suvorexant discontinuation produced rebound insomnia in approximately 9% of long-term users, similar in magnitude to lemborexant's trial data. [7] No head-to-head discontinuation trial between the two DORAs has been published.

Who Is at Highest Risk for Discontinuation Symptoms?

Not every patient stopping lemborexant experiences problems. Several clinical features raise the probability of a more difficult discontinuation.

Duration and Dose

Longer duration of use and higher doses (10 mg vs. 5 mg) are associated with greater pharmacological adaptation. The prescribing information notes that higher doses produced numerically higher rebound rates in SUNRISE-2, though neither was statistically worse than placebo. [3]

Underlying Anxiety Disorders

Patients with generalized anxiety disorder or panic disorder may be more sensitive to any pro-arousal shift from orexin pathway normalization. A 2020 review in the Journal of Clinical Sleep Medicine found that comorbid anxiety independently predicted rebound insomnia after hypnotic discontinuation across drug classes. [10]

Concurrent Psychotropic Polypharmacy

Lemborexant is a CYP3A4 substrate. Co-administration with moderate or strong CYP3A4 inhibitors (for example, fluconazole, diltiazem) increases lemborexant exposure and could theoretically intensify the offset effect when those inhibitors are also stopped. The FDA label restricts lemborexant to 5 mg with moderate CYP3A4 inhibitors and contraindicates co-use with strong inhibitors. [3]

Clinical Approach to Stopping Lemborexant

The FDA label does not require a taper. That permissive stance reflects the controlled trial data showing no statistically significant rebound exceeding baseline at the group level. Yet individual patients vary. [3]

The HealthRX clinical team recommends the following structured discontinuation framework based on available trial data, FDA labeling, and published DORA pharmacology:

Step 1 (weeks 1 to 2). If the patient is on 10 mg, reduce to 5 mg for at least two weeks before stopping entirely. This step-down is not mandated by the label but aligns with general pharmacological principles of gradual offset.

Step 2 (at discontinuation). Stop 5 mg on a night preceding a lower-stakes day. Alert the patient to expect one to five nights of lighter or more disrupted sleep.

Step 3 (weeks 1 to 2 post-stop). Follow up at two weeks by phone or secure message. Document sleep onset latency, total sleep time, and any anxiety or mood symptoms. Use the Insomnia Severity Index (ISI) to quantify severity. [11]

Step 4 (if rebound persists beyond two weeks). If ISI score remains at 15 or above at two weeks post-stop, evaluate for recurrent insomnia disorder independent of discontinuation effect, and consider referral for Cognitive Behavioral Therapy for Insomnia (CBT-I). AASM guidelines endorse CBT-I as first-line therapy for chronic insomnia. [8]

Cognitive Behavioral Therapy for Insomnia as an Exit Strategy

CBT-I is the most evidence-supported non-pharmacological intervention for insomnia and serves a dual role: it treats the underlying disorder and reduces reliance on pharmacotherapy.

A 2022 meta-analysis in Sleep Medicine Reviews (N=2,189 across 20 RCTs) found that CBT-I reduced sleep onset latency by a mean of 19.1 minutes and improved sleep efficiency by 9.5 percentage points compared with control conditions. [12] Patients who complete CBT-I before or during hypnotic discontinuation are significantly more likely to remain off medication at 12-month follow-up. [12]

The practical implication: beginning CBT-I four to six weeks before planned lemborexant discontinuation gives patients behavioral tools to buffer against rebound nights.

Rare and Serious Adverse Events Beyond Discontinuation

Stopping lemborexant is one piece of the adverse event picture. The full spectrum of rare events deserves documentation.

Sleep Paralysis and Hypnagogic Hallucinations

Because orexin stabilizes the boundary between wakefulness and REM sleep, DORAs can blur that boundary. The lemborexant label reports sleep paralysis in 2% and hypnagogic or hypnopompic hallucinations in approximately 1% of trial participants, compared with <1% placebo. [3] These events are typically brief but can be alarming.

Cataplexy-Like Events

The label carries a warning for cataplexy-like symptoms. In the SUNRISE trials, one lemborexant-treated participant experienced a cataplexy-like event. [3] The prescribing information contraindicates use in patients with narcolepsy, a population already prone to cataplexy. [3]

Excessive Daytime Sleepiness

Somnolence and excessive daytime sleepiness (EDS) were the most common adverse events in clinical trials, occurring in 10% (5 mg) and 17% (10 mg) of patients versus 7% placebo in SUNRISE-1. [1] EDS is a dose-dependent on-treatment effect rather than a discontinuation symptom, but it informs dose selection and the decision to taper from 10 mg to 5 mg before stopping.

Complex Sleep Behaviors

Complex sleep behaviors (sleepwalking, sleep driving, sleep-related eating) represent an FDA class warning for all prescription hypnotics, including lemborexant. [13] The FDA issued a 2019 safety communication requiring a boxed warning on all hypnotic sedatives after receiving reports of serious injuries and deaths. Lemborexant's label carries this warning. If any complex sleep behavior occurs, the drug should be stopped immediately. [13]

Regulatory and Post-Market Surveillance Context

The FDA approved lemborexant under NDA 212028. Post-approval, Eisai (the manufacturer) conducted a required post-marketing study evaluating abuse potential. That study, completed in 2021, found lemborexant produced subjective "drug liking" scores lower than triazolam (a Schedule IV benzodiazepine) but higher than placebo in recreational sedative users. [3] The DEA subsequently placed lemborexant in Schedule IV, reflecting real but moderate abuse potential.

A 2023 analysis of insurance claims data (N=24,601 lemborexant initiators) found a 12-month discontinuation rate of 58%, with the most common reasons being perceived lack of efficacy (31%) and side effects including daytime sedation (18%). [14] Withdrawal-specific discontinuation accounted for fewer than 3% of stated reasons. [14]

The American Academy of Sleep Medicine's 2017 guideline on adult insomnia states: "We suggest that clinicians use pharmacological therapy in addition to, or as an alternative to, CBT-I when the clinical situation warrants pharmacotherapy." [8] This conditional recommendation underscores that long-term hypnotic use should always include a plan for eventual discontinuation.

A 2021 review in Sleep Medicine Clinics noted: "Dual orexin receptor antagonists represent a mechanistic departure from GABAergic hypnotics, and current evidence does not support classifying DORA discontinuation as a true withdrawal syndrome in the manner defined for benzodiazepines." [2]

Dayvigo Drug Interactions That Affect Discontinuation Timing

Several drug interactions affect how lemborexant behaves at the time of discontinuation and deserve explicit attention.

CYP3A4 inducers such as rifampin, carbamazepine, and St. John's Wort accelerate lemborexant metabolism, reducing plasma levels and potentially precipitating earlier-than-expected offset. Patients starting a CYP3A4 inducer while on lemborexant may experience an abrupt pharmacological discontinuation effect without stopping the drug intentionally. [3]

Central nervous system depressants including alcohol, opioids, and other sedatives potentiate lemborexant's on-treatment sedation. Stopping lemborexant in a patient still using other CNS depressants may unmask previously masked insomnia with a compounded arousal rebound. The FDA label recommends avoiding concurrent alcohol use. [3]

Patient Counseling Checklist Before Stopping Lemborexant

Clinicians prescribing lemborexant should document the following points in the shared decision-making record at any visit where discontinuation is being considered:

• Expected duration of mild sleep disruption (typically two to seven nights)
• Option to step down from 10 mg to 5 mg for two weeks before stopping
• Signs that warrant calling the office (complex sleep behaviors, persisting anxiety beyond two weeks, any thoughts of self-harm from sleep deprivation)
• Concurrent CBT-I referral or digital CBT-I program if not already initiated
• Review of current CYP3A4 interacting medications

A 2021 patient-reported outcomes study of lemborexant users (N=318) found that 74% reported no counseling about discontinuation at the time of first prescription. [15] Pre-emptive counseling is associated with better patient-reported confidence in managing sleep after stopping any hypnotic. [15]